Physician Familiarity May Determine Epkinly Uptake In Follicular Lymphoma
Newly Approved Drug Going Up Against Roche’s Lunsumio
AbbVie/Genmab’s anti-CD20 bispecific is the first subcutaneous drug in the class to win approval for FL, but despite that advantage, doctors may pick the drug they know best.
